Qube Research & Technologies LTD Pharvaris N.V. Call Options Transaction History
Qube Research & Technologies LTD
- $65.7 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PHVS
# of Institutions
51Shares Held
39.6MCall Options Held
0Put Options Held
0-
General Atlantic LLC New York, NY7.53MShares$142 Million3.99% of portfolio
-
Foresite Capital Management Iv, LLC Larkspur, CA4.4MShares$82.8 Million53.23% of portfolio
-
Ven Bio Partners LLC San Francisco, CA4.29MShares$80.8 Million65.3% of portfolio
-
Viking Global Investors LP3.65MShares$68.8 Million0.26% of portfolio
-
Vr Adviser, LLC New York, NY3.4MShares$63.9 Million6.51% of portfolio
About Pharvaris N.V.
- Ticker PHVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,766,000
- Market Cap $636M
- Description
- Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...